New hope for lymphoma patients: drug combo shows promise in phase 3 trial
Disease control
Completed
This study tested whether adding the drug orelabrutinib to standard chemotherapy (R-CHOP) works better than chemotherapy alone for people with untreated mantle cell lymphoma. Only 3 patients took part. The main goal was to see if the combination delays cancer growth. This is a di…
Phase: PHASE3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC